Jonathan Bush

Dr. Jonathan Bush

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
NDNicholas A.J. Dawson
Nicholas A.J. Dawson
CLCaroline Lamarche
Caroline Lamarche
RHRomy E. Hoeppli
Romy E. Hoeppli
PBPeter Bergqvist
Peter Bergqvist
VFVivian C.W. Fung
Vivian C.W. Fung
MLMegan K. Levings
Megan K. Levings
Chimeric antigen receptor (CAR) technology can be used to engineer the antigen specificity of regulatory T cells (Tregs) and improve their potency as an adoptive cell therapy in multiple disease models. As synthetic receptors, CARs carry the risk of immunogenicity, particularly when derived from nonhuman antibodies. Using an HLA-A*02:01–specific CAR (A2-CAR) encoding a single-chain variable fragment (Fv) derived from a mouse antibody, we developed a panel of 20 humanized A2-CARs (hA2-CARs). Systematic testing demonstrated variations in expression, and ability to bind HLA-A*02:01 and stimulate human Treg suppression in vitro. In addition, we developed a new method to comprehensively map the alloantigen specificity of CARs, revealing that humanization reduced HLA-A cross-reactivity. In vivo bioluminescence imaging showed rapid trafficking and persistence of hA2-CAR Tregs in A2-expressing allografts, with eventual migration to draining lymph nodes. Adoptive transfer of hA2-CAR Tregs suppressed HLA-A2 + cell–mediated xenogeneic graft-versus-host disease and diminished rejection of human HLA-A2 + skin allografts. These data provide a platform for systematic development and specificity testing of humanized alloantigen-specific CARs that can be used to engineer specificity and homing of therapeutic Tregs.

1 June 2013 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
JBJonathan Bush
Jonathan Bush
TWTerry Wuerz
Terry Wuerz
JEJohn M. Embil
John M. Embil
MBMarc R. Del Bigio
Marc R. Del Bigio
PMPatrick J. McDonald
Patrick J. McDonald
SKSherry Krawitz
Sherry Krawitz

17 May 2021 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
MAMamy Andrianteranagna
Mamy Andrianteranagna
JCJoanna Cyrta
Joanna Cyrta
JMJulien Masliah‐Planchon
Julien Masliah‐Planchon
KNKarolina Nemes
Karolina Nemes
ACAlice Corsia
Alice Corsia
FBFranck Bourdeaut
Franck Bourdeaut

1 August 2018 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
NMNissreen Mohammad
Nissreen Mohammad
VAVishal Avinashi
Vishal Avinashi
ECEdmond Chan
Edmond Chan
BVBruce A Vallance
Bruce A Vallance
EPElodie Portales‐Casamar
Elodie Portales‐Casamar
JBJonathan Bush
Jonathan Bush

12 August 2019 in Pediatric and Developmental Pathology
Verified
Journal Article
Open access
PDF file
JSJessica Saunders
Jessica Saunders
KIKatrina Ingley
Katrina Ingley
XWXiu Qing Wang
Xiu Qing Wang
MHMelissa Harvey
Melissa Harvey
LALinlea Armstrong
Linlea Armstrong
JBJonathan Bush
Jonathan Bush
Malignant rhabdoid tumors and atypical teratoid/rhabdoid tumors of the central nervous system are primitive malignancies associated with a poor prognosis. These tumors have previously been characterized by inactivation of the switch/sucrose nonfermenting (SWI/SNF) chromatin remodeling complex protein integrase interactor 1 (INI1), encoded by the SMARCB1 gene. In the last decade, sporadic publications have shown that a different SWI/SNF protein, brahma-related gene 1 (BRG1), encoded by the SMARCA4 gene, is associated with a similar rhabdoid phenotype and possible germline mutation termed rhabdoid tumor predisposition syndrome type 2. We sought to determine the presence of BRG1 expression in pediatric embryonal tumors. Using a local tissue microarray consisting of 28 tumors diagnosed as having an undifferentiated, polyphenotypic, or rhabdoid morphology, expression of BRG1 by immunohistochemistry was performed. Four cases showed loss of INI1, while 3 of the remaining 24 cases demonstrated loss of BRG1. Two cases were diagnosed as soft tissue sarcomas, and 1 case was diagnosed as a small cell carcinoma of the ovary, hypercalcemic type. Survival ranged from less than 6 months after diagnosis to more than 5 years at the time of last follow-up. In conclusion, we demonstrate that BRG1 immunohistochemistry is a useful second-line immunostain for the workup of undifferentiated, polyphenotypic or rhabdoid pediatric tumors that demonstrate retained expression of INI1.

22 May 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AAAmy E. Armstrong
Amy E. Armstrong
DWDebra E. Weese‐Mayer
Debra E. Weese‐Mayer
AMAmir Mian
Amir Mian
JMJohn M. Maris
John M. Maris
VBVandana Batra
Vandana Batra
DWDavid O. Walterhouse
David O. Walterhouse